News
The following is a listing of news and media statements issued by Dimerix Bioscience.
February 2009
Dimerix Bioscience Pty Ltd announced that it has closed an investment round in excess of $1.4 million. Dimerix will apply funding to expand its contractual profiling of drugs against GPCRs that form heterodimers, in addition to continuing its own development programs. 
PDF [0.1MB]
* Building a new conceptual framework for receptor heteromers. Ferre et al. Nature Chemical Biology 5, 131 - 134 (2009)
April 2008
Dimerix demonstrates that angiotensin ligand effects through heterodimers may not be blocked by marketed angiotensin receptor blockers (ARBs). Dimerix has novel and known angiotensin heterodimers. PDF [0.4MB]
September 2007
Dimerix Bioscience is using its G-Protein Coupled Receptor-Heterodimer Identification Technology (GPCR-HIT) to develop the next generation of drugs targeting G-Protein Coupled Receptors (GPCRs). PDF [0.1MB]
July 2007
Dimerix Bioscience announces that it has closed a funding round with current investor Foundation Capital and its partner Stone Ridge Ventures. PDF [0.1MB]
April 2007
Dimerix announces a collaboration with the National Center for Drug Screening in China to scale its GPCR-HIT assay for high-throughput screening against heterodimer targets. PDF [0.1MB]
December 2006
Dimerix announces that it has acquired rights to a new technology from the University of Western Australia. The technology inventors, A/Professor Karin Eidne, Dr Kevin Pfleger and co-workers based in the Laboratory for Molecular Endocrinology at the Western Australian Institute for Medical Research have successfully tested a novel cellular assay (GPCR-HIT) on a number of GPCR heterodimer combinations.
August 2006
Dimerix Bioscience have announced Board and Management changes with the appointment of Dr James Williams as CEO and Executive Director, and Dr Tony Mason as Scientific Advisor. James and Tony bring significant scientific and commercial experience to the Dimerix team.
September 2005
Dimerix Bioscience Pty Ltd today announced that it has closed a Series A financing which was led by venture capital firm Foundation Capital, and supported by the Murdoch Westscheme Enterprise Partnership fund. PDF [0.1MB]
May 2005
Dimerix Bioscience is pleased to announce that it has been offered a $200,000 'Commercial Ready' grant by AusIndustry to support the development of a new class of drugs targeting G-protein Coupled Receptors (GPCRs) in a way that exploits their ability to form complexes to achieve enhanced therapeutic benefits. PDF [0.1MB]
March 2005
Starpharma and QPSX announced the launch of a new start-up biotechnology company as foundation shareholders. The company, Dimerix Bioscience Pty Ltd, has also commenced a joint venture with Starpharma to investigate the applications of Starpharma's dendrimer nano-particles together with the Dimerix Collision technology, to create a new class of polyvalent pharmaceutical compounds. Dendrimers allow chemists to produce highly defined and biocompatible nanoscale objects built from the 'bottom up', which are particularly attractive to the challenges presented by GPCR complexes. Starpharma PDF [0.1MB] - QPSX PDF [0.1MB]
